JP2011506436A - 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 - Google Patents

細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 Download PDF

Info

Publication number
JP2011506436A
JP2011506436A JP2010537941A JP2010537941A JP2011506436A JP 2011506436 A JP2011506436 A JP 2011506436A JP 2010537941 A JP2010537941 A JP 2010537941A JP 2010537941 A JP2010537941 A JP 2010537941A JP 2011506436 A JP2011506436 A JP 2011506436A
Authority
JP
Japan
Prior art keywords
day
dosage
days
administered
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010537941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506436A5 (https=
Inventor
イスラエル リオス
シンシア ダブリュー． タットヒル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of JP2011506436A publication Critical patent/JP2011506436A/ja
Publication of JP2011506436A5 publication Critical patent/JP2011506436A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010537941A 2007-12-12 2008-12-08 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 Withdrawn JP2011506436A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1310107P 2007-12-12 2007-12-12
PCT/US2008/013480 WO2009075813A1 (en) 2007-12-12 2008-12-08 Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)

Publications (2)

Publication Number Publication Date
JP2011506436A true JP2011506436A (ja) 2011-03-03
JP2011506436A5 JP2011506436A5 (https=) 2012-01-26

Family

ID=40755783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537941A Withdrawn JP2011506436A (ja) 2007-12-12 2008-12-08 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法

Country Status (8)

Country Link
US (1) US20100330093A1 (https=)
EP (1) EP2240195A4 (https=)
JP (1) JP2011506436A (https=)
CN (1) CN101896190A (https=)
AR (1) AR069682A1 (https=)
AU (1) AU2008335840A1 (https=)
CA (1) CA2709027A1 (https=)
WO (1) WO2009075813A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016133059A1 (ja) * 2015-02-16 2016-08-25 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
JP2018501192A (ja) * 2014-10-21 2018-01-18 サイクロン ファーマシューティカルズ， インク．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 免疫刺激剤による癌治療

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
WO2013177102A2 (en) * 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
IT201900016310A1 (it) * 2019-09-13 2021-03-13 Luigina Romani Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501192A (ja) * 2014-10-21 2018-01-18 サイクロン ファーマシューティカルズ， インク．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 免疫刺激剤による癌治療
JP2021088557A (ja) * 2014-10-21 2021-06-10 サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． 免疫刺激剤による癌治療
JP7175334B2 (ja) 2014-10-21 2022-11-18 サイクロン ファーマシューティカルズ インターナショナル エルティーディー． 免疫刺激剤による癌治療
WO2016133059A1 (ja) * 2015-02-16 2016-08-25 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
US10806787B2 (en) 2015-02-16 2020-10-20 Pharma Foods International Co., Ltd. Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof

Also Published As

Publication number Publication date
US20100330093A1 (en) 2010-12-30
AR069682A1 (es) 2010-02-10
WO2009075813A1 (en) 2009-06-18
EP2240195A1 (en) 2010-10-20
EP2240195A4 (en) 2011-12-21
CA2709027A1 (en) 2009-06-18
CN101896190A (zh) 2010-11-24
AU2008335840A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP2009542623A (ja) Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療
US20210228571A1 (en) Methods and compositions for treating cancer
CN112135639A (zh) 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
US20220313626A1 (en) Small molecule inhibitors for treating cancer in a subject having tumors with high interstitial pressure
US8569280B2 (en) Methods for the treatment of multiple myeloma
US20060035825A1 (en) Alpha 5 beta 1 and its ability to regulate the cell survival pathway
JP2011506467A (ja) 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
US20180243366A1 (en) Drug containing recombinant mistletoe lectins for treating malignant melanoma
CN111867678A (zh) 治疗黑色素瘤的方法
US20230121867A1 (en) Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
WO2021243207A1 (en) Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
WO2021138582A1 (en) Fusion proteins and methods of use thereof
JP2022551672A (ja) 乳癌治療法
CN120826242A (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
AU2024208037A1 (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
WO2018209017A1 (en) Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor
US11497793B2 (en) Compositions and methods for treating glioblastoma
US20260098097A1 (en) Immunotoxin-based targeted therapy for cancer
JP7317343B2 (ja) 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤
KR20200017495A (ko) Nk-92 세포 및 il-15 효능제의 조합 요법
US20220409611A1 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions
WO2025160930A1 (zh) 母帕司汀(Muparfostat)治疗胰腺癌的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111201

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130520